AG2001

AG2001 is an investigational biologic drug being developed as an oral therapy for acute bronchitis, with ongoing evaluation in a randomized, double-blind, active-controlled Phase 3 clinical trial in adults presenting with acute bronchitis symptoms such as cough and sputum.[1][3][5][8][11] In this study, AG2001 is administered orally three times daily for 7 days and is being compared against two active control regimens (AG20011 and AG20012) using the Bronchitis Severity Score and patient-reported outcome measures to assess efficacy and safety.[1][3][11] The precise molecular identity, target, and detailed mechanism of action of AG2001 have not been publicly disclosed, but DrugBank classifies it as a biologic drug under investigation for acute tracheobronchitis/acute bronchitis.[5][7][8]